|Free Dividend Report|
|Stock Splits Calendar|
|SCLN Stock Split History|
|Preferred Stock Newsletter|
|SCLN Options Chain|
|SCLN Message Board|
SCLN (SCLN) has 1 split in our SCLN split history database. The split for SCLN took place on August 09, 1993. This was a 1 for 3 reverse split, meaning for each 3 shares of SCLN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 333.333333333333 share position following the split.
When a company such as SCLN conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SCLN split history from start to finish, an original position size of 1000 shares would have turned into 333.333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SCLN shares, starting with a $10,000 purchase of SCLN, presented on a split-history-adjusted basis factoring in the complete SCLN split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||11.17%|
|SciClone Pharmaceuticals is a pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. Co.'s business is focused primarily on the People's Republic of China. Co. operates in two segments which are based on the nature and location of its customers: China and the Rest of the World, which includes its U.S. and Hong Kong operations. Co.'s primary product, ZADAXIN (thymalfasin), is approved in over 30 countries and may be used for the treatment of the hepatitis B virus, hepatitis C virus, and certain cancers, and as an immune system enhancer according to the local regulatory approvals Co. has in these countries. According to our SCLN split history records, SCLN has had 1 split.|
|SCLN Split History Table|
|08/09/1993||1 for 3|
|Healthcare Stock Splits|
|SCLN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|